Literature DB >> 23383741

Why does allergic contact dermatitis exist?

J P McFadden1, P Puangpet, D A Basketter, R J Dearman, I Kimber.   

Abstract

The skin immune system's propensity to produce allergic contact dermatitis (ACD) to harmless chemicals, while otherwise being an efficient defence system, represents a dermatological paradox. We postulate that a major role in signalling in ACD is played by Toll-like receptor (TLR)2 and TLR4, and arises from their activation by extracellular danger-associated molecular patterns (DAMPs). Ligand activation of TLR4/2 results in the expression of interleukins (ILs) IL-1β, IL-6, IL-12, IL-18 and IL-23, tumour necrosis factor-α and interferon-α. These cytokines promote acquisition of sensitization, and facilitate elicitation of contact allergy via multiple mechanisms, including the recruitment of CD4+ Th1 and Th17 cells. As Th1 cells secrete large amounts of DAMPs, a DAMP immune circuit (positive-feedback loop) is created. This is an important driver of skin sensitization and skin inflammation. Pathogenic extracellular bacteria, but not commensal bacteria, produce pathogen-associated molecular pattern molecules, which stimulate the expression of Th1- and Th17-promoting cytokines via TLR2 and TLR4. This also induces an immune circuit. The ability of the skin immune system to activate host defence mechanisms and to distinguish between pathogenic bacteria and commensals provides an explanation for why skin sensitization and ACD develop, as they are processes that rely on the same biological pathways. These pathways may also shed light on the pathogenesis of chronic pustular inflammatory dermatoses (e.g. acne vulgaris). The existence of safety signals from commensal bacteria, which prevent initiation of these pathways, may provide opportunities for novel therapeutic approaches to the treatment of inflammatory skin diseases.
© 2013 The Authors. BJD © 2013 British Association of Dermatologists.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23383741     DOI: 10.1111/bjd.12145

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  7 in total

1.  Effects of baicalin cream in two mouse models: 2,4-dinitrofluorobenzene-induced contact hypersensitivity and mouse tail test for psoriasis.

Authors:  Jie Wu; Hong Li; Ming Li
Journal:  Int J Clin Exp Med       Date:  2015-02-15

2.  Role of ROS and HMGB1 in contact allergen-induced IL-18 production in human keratinocytes.

Authors:  Valentina Galbiati; Angela Papale; Corrado L Galli; Marina Marinovich; Emanuela Corsini
Journal:  J Invest Dermatol       Date:  2014-04-29       Impact factor: 8.551

3.  Identification and Characterization of Circulating Naïve CD4+ and CD8+ T Cells Recognizing Nickel.

Authors:  Rami Bechara; Sabrina Pollastro; Marie Eliane Azoury; Natacha Szely; Bernard Maillère; Niek de Vries; Marc Pallardy
Journal:  Front Immunol       Date:  2019-06-12       Impact factor: 7.561

Review 4.  IL-18 and Cutaneous Inflammatory Diseases.

Authors:  Ji Hyun Lee; Dae Ho Cho; Hyun Jeong Park
Journal:  Int J Mol Sci       Date:  2015-12-09       Impact factor: 5.923

5.  Protective effect of small molecule analogues of the Acanthocheilonema viteae secreted product ES-62 on oxazolone-induced ear inflammation.

Authors:  Lamyaa Al-Riyami; David T Rodgers; Justyna Rzepecka; Miguel A Pineda; Colin J Suckling; Margaret M Harnett; William Harnett
Journal:  Exp Parasitol       Date:  2015-03-30       Impact factor: 2.011

6.  Oxazolone-induced contact hypersensitivity reduces lymphatic drainage but enhances the induction of adaptive immunity.

Authors:  David Aebischer; Ann-Helen Willrodt; Cornelia Halin
Journal:  PLoS One       Date:  2014-06-09       Impact factor: 3.240

7.  Harnessing co-operative immune augmentation by contact allergens to enhance the efficacy of viral vaccines.

Authors:  Louise S Cunningham; John P McFadden; David A Basketter; Felicity J Ferguson; Ian R White; Ian Kimber
Journal:  Contact Dermatitis       Date:  2020-09-04       Impact factor: 6.419

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.